Northern Trust’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-366,059
| Closed | -$13.8M | – | 4680 |
|
|
2021
Q1 | $13.8M | Sell |
366,059
-21,197
| -5% | -$529K | ﹤0.01% | 2078 |
|
|
2020
Q4 | $6.59M | Buy |
387,256
+35,080
| +10% | +$440K | ﹤0.01% | 2509 |
|
|
2020
Q3 | $1.66M | Sell |
352,176
-10,480
| -3% | -$53.2K | ﹤0.01% | 3143 |
|
|
2020
Q2 | $2.21M | Sell |
362,656
-63,994
| -15% | -$264K | ﹤0.01% | 2992 |
|
|
2020
Q1 | $969K | Buy |
426,650
+31,273
| +8% | +$133K | ﹤0.01% | 3236 |
|
|
2019
Q4 | $1.81M | Sell |
395,377
-30,652
| -7% | -$121K | ﹤0.01% | 3186 |
|
|
2019
Q3 | $1.65M | Sell |
426,029
-17,162
| -4% | -$94.2K | ﹤0.01% | 3210 |
|
|
2019
Q2 | $2.67M | Buy |
443,191
+12,054
| +3% | +$115K | ﹤0.01% | 2906 |
|
|
2019
Q1 | $5.78M | Buy |
431,137
+5,362
| +1% | +$61.2K | ﹤0.01% | 2477 |
|
|
2018
Q4 | $3.96M | Buy |
425,775
+2,278
| +0.5% | +$27.1K | ﹤0.01% | 2646 |
|
|
2018
Q3 | $5.89M | Buy |
423,497
+28,619
| +7% | +$426K | ﹤0.01% | 2598 |
|
|
2018
Q2 | $6.24M | Buy |
394,878
+24,838
| +7% | +$433K | ﹤0.01% | 2565 |
|
|
2018
Q1 | $6.36M | Buy |
370,040
+46,742
| +14% | +$912K | ﹤0.01% | 2443 |
|
|
2017
Q4 | $7.09M | Buy |
323,298
+1,014
| +0.3% | +$32.6K | ﹤0.01% | 2399 |
|
|
2017
Q3 | $13.2M | Sell |
322,284
-13,204
| -4% | -$415K | ﹤0.01% | 2017 |
|
|
2017
Q2 | $10.1M | Buy |
335,488
+3,770
| +1% | +$118K | ﹤0.01% | 2180 |
|
|
2017
Q1 | $12M | Buy |
331,718
+1,262
| +0.4% | +$55.6K | ﹤0.01% | 1989 |
|
|
2016
Q4 | $16.6M | Sell |
330,456
-7,287
| -2% | -$383K | 0.01% | 1737 |
|
|
2016
Q3 | $17.7M | Buy |
337,743
+12,809
| +4% | +$612K | 0.01% | 1683 |
|
|
2016
Q2 | $13.4M | Buy |
324,934
+24,941
| +8% | +$1.08M | ﹤0.01% | 1817 |
|
|
2016
Q1 | $11.4M | Buy |
299,993
+2,813
| +0.9% | +$96.7K | ﹤0.01% | 1877 |
|
|
2015
Q4 | $12.3M | Buy |
297,180
+25,234
| +9% | +$846K | ﹤0.01% | 1854 |
|
|
2015
Q3 | $4.19M | Buy |
271,946
+37,018
| +16% | +$796K | ﹤0.01% | 2552 |
|
|
2015
Q2 | $5.84M | Buy |
234,928
+18,120
| +8% | +$404K | ﹤0.01% | 2427 |
|
|
2015
Q1 | $4.95M | Buy |
216,808
+51,393
| +31% | +$1.3M | ﹤0.01% | 2510 |
|
|
2014
Q4 | $4.47M | Sell |
165,415
-1,757
| -1% | -$30.2K | ﹤0.01% | 2582 |
|
|
2014
Q3 | $1.96M | Buy |
167,172
+78,896
| +89% | +$995K | ﹤0.01% | 3116 |
|
|
2014
Q2 | $1.37M | Buy |
88,276
+14,436
| +20% | +$207K | ﹤0.01% | 3274 |
|
|
2014
Q1 | $1.45M | Sell |
73,840
-3,327
| -4% | -$56.5K | ﹤0.01% | 3278 |
|
|
2013
Q4 | $1.3M | Buy |
+77,167
| New | +$959K | ﹤0.01% | 3319 |
|
Northern Trust's FPRX Position: Q2 2021 in Review
Northern Trust sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 366,059 shares — an estimated $13.8M sold.
Northern Trust first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $17.7M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Northern Trust reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Northern Trust sold 366,059 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $13.8M.
- Northern Trust first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Northern Trust's Five Prime Therapeutics, Inc. position peaked at $17.7M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Northern Trust's 13F filing for Q2 2021, filed 13 Aug 2021.